Ac immune reports q2 2020 financial results and provides business update

Ac immune reports q2 2020 financial results and provides business update.ac immune sa - top line phase 2 data expected in second half of 2020 for anti-tau antibody semorinemab.ac immune sa - revenues for three months ended june 30, 2020 totaled chf 1.3 million.ac immune sa - had a total cash balance of chf 262.5 million.ac immune sa - qtrly loss per share chf 0.22.

ACIU Ratings Summary

ACIU Quant Ranking